Biopharma Therapeutics and Platforms M&A slowed sharply in Q3 2026, with value falling far faster than deal count. Deals dropped 23.1% to 40 from 52 in Q2, while total value, including milestones, fell 81.1% to $15.3B from $81.1B. Upfront payments shrank too: the average fell 53.6% to $836M and the median 42.3% to $450M. Biologics accounted for 75.8% of total value. By therapy area, autoimmune disease led in value with $5.4B, and neurologic disorders led in count with 9 deals.
Five deals stood out. Eli Lilly agreed to buy Merida Biosciences for up to $2.8B, gaining a platform that selectively clears disease-causing antibodies in autoimmune and allergic diseases. Argenx bought Forte Biosciences for about $2.2B, adding a Phase 2 antibody for celiac disease, vitiligo, and alopecia areata. Samsung Biologics agreed to buy PolyPeptide for about $1.8B, expanding into peptide manufacturing for obesity and diabetes treatments. Novartis bought Myricx Bio for up to $1.5B to add early-stage antibody-drug conjugates for cancer. Jazz Pharmaceuticals bought Actio Biosciences for up to $1.3B, securing a Phase 1/2 drug for a rare genetic epilepsy.
Biopharma Therapeutics and Platforms M&A slowed sharply in Q3 2026, with deal count down 23.1% to 40 from 52 in Q2. Total M&A value including contingents dropped 81.1% to $15.3B from $81.1B, while M&A cash value excluding contingents declined 83.7% to $10.9B from $66.7B. Upfront payments also contracted. Average upfront cash and equity fell 53.6% to $836M from $1.8B, and the median decreased 42.3% to $450M from $780M. Q2 and Q3 2026 together recorded 92 M&A deals, worth $96.4B including contingents and $77.6B in cash value excluding contingents. Overall, with value falling far faster than deal count, the Q3 slowdown reflected smaller transactions as well as fewer deals.
Biopharma Therapeutic and Platform M&A by Top Modalities – Q3 2026
Biologics, which include antibodies, DNA, RNA, and proteins, led Biopharma Therapeutics and Platforms M&A in Q3 2026. The modality recorded 19 deals (48.7% of the listed deals), valued at $11.6B including contingents and $9.1B excluding contingents. Average upfront cash and equity reached $1.3B, with a median of $1.1B. Small molecules followed with 15 deals (38.5%), representing $3.4B including contingents and $1.6B excluding contingents. Their average and median upfront values were $326M and $275M, respectively. Cell therapy ranked third with 5 deals (12.8%), valued at $300M including contingents and $100M excluding contingents. Both its average and median upfront values stood at $140M. Together, the three modalities accounted for 39 deals, worth $15.3B including contingents and a reported $10.9B excluding contingents. Overall, biologics dominated, contributing 75.8% of total M&A value including contingents against a 48.7% share of deals.
Biopharma Therapeutic and Platform M&A by Top Therapy Areas – Q3 2026
In Q3 2026, autoimmune led the top therapy areas in Biopharma Therapeutics and Platforms M&A by value including contingents. Its 6 deals reached $5.4B, or 37.2% of combined therapy-area value, and $5.1B excluding contingents. Average and median upfront cash and equity were both $2.5B. Endocrine/metabolic ranked second with 7 deals worth $2.9B; average and median upfronts were both $1.1B. Neurologic recorded the most deals at 9 (30% of the therapy-area total), valued at $2.2B. Its average and median upfront values were $360M and $251M, respectively. Cancer followed with 4 deals worth $1.5B, ahead of ophthalmic with 2 deals valued at $1.4B. Infectious diseases and dermatologic each recorded 1 deal, valued at $800M and $300M, respectively. In total, the seven therapy areas accounted for 30 deals, worth $14.5B including contingents and $10.2B excluding contingents.
Prominent Biopharma Therapeutics and Platforms M&A in Q3 2026
Eli Lilly acquiring Merida Biosciences – August 2026
Eli Lilly agreed to acquire Merida Biosciences for up to $2.8B in cash, comprising an upfront payment and contingent milestones. The deal gives Lilly an antibody-degradation platform designed to selectively clear disease-causing autoantibodies while preserving normal immune function. Phase 1 MER-511 leads the pipeline in Graves’ disease and thyroid eye disease. IND-enabling MER-769 targets allergic diseases, including asthma, atopic dermatitis, urticaria, and food allergy. Merida also has MER-683 for primary membranous nephropathy and an undisclosed program. Closing is expected in Q4 2026.
Argenx acquiring Forte Biosciences – July 2026
Argenx agreed to acquire Forte Biosciences for $77 per share in cash, valuing Forte’s equity at about $2.2B. The price carried a 41% one-day premium and a premium of about 86% to Forte’s volume-weighted average price. Forte’s lead asset was FB102, a Phase 2 anti-CD122 antibody in celiac disease, vitiligo and alopecia areata. Data from the celiac disease Phase 2 trial and the alopecia areata trial are due in 2026. The deal moves Argenx from strategic investor to owner. FB102 joins an antibody portfolio that includes efgartigimod, empasiprubart, adimanebart, and ARGX-121. Argenx completed the acquisition on August 27, 2026.
Samsung Biologics acquiring PolyPeptide – July 2026
Samsung Biologics agreed to acquire PolyPeptide for CHF 44.31 (about $54.90) per share in cash, valuing PolyPeptide’s equity at about CHF 1.5B ($1.8B). The price is 6.1% above the last close, 40% above the unaffected share price, and 11.6% above the 60-day volume-weighted average price. The gap between the 40% and 6.1% premiums reflects a share price rise ahead of the announcement. PolyPeptide is a contract manufacturer of synthetic peptide and oligonucleotide drug ingredients. The deal takes Samsung beyond antibodies and antibody-drug conjugates into peptides, particularly GLP-1 and other obesity and diabetes treatments. On August 28, 2026, Samsung announced a KRW 3 trillion ($2.2B) rights offering, earmarking $2.0B for PolyPeptide and the rest for Songdo manufacturing capacity. Closing is expected by the end of 2026.
Novartis acquiring Myricx Bio – July 2026
Novartis agreed to acquire Sofinnova-backed Myricx Bio for up to $1.5B; $1.1B upfront plus up to $400M in milestones. Myricx brings two preclinical antibody-drug conjugate programs, targeting B7-H3 in solid tumors and HER2 in breast, gastric, and other cancers. Its N-myristoyltransferase inhibitor payload platform gives Novartis a novel mechanism for its cancer drug conjugates. Novartis completed the acquisition on August 28, 2026.
Jazz Pharmaceuticals acquiring Actio Biosciences – August 2026
Jazz Pharmaceuticals agreed to acquire Actio Biosciences for up to $1.3B; $820M upfront plus up to $500M in approval and commercial milestones. The deal gives Jazz ABS-1230, a Phase 1/2 small molecule for rare KCNT1-related epilepsy, complementing Epidiolex in its rare epilepsy portfolio. Jazz spun out Phase 1 ABS-0871 for Charcot-Marie-Tooth, other early-stage programs, and staff into a new private company funded by existing investors. Jazz took a minority stake and related rights, keeping exposure to those programs. Jazz completed the acquisition on September 15, 2026.
Also check out Biopharma Therapeutics and Platforms R&D Partnerships – Q3 2026 Review
